vs
Idexx Laboratories（IDXX）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是Idexx Laboratories的1.3倍（$1.4B vs $1.1B），瑞思迈净利率更高（27.6% vs 22.8%，领先4.8%），Idexx Laboratories同比增速更快（14.3% vs 11.0%），过去两年瑞思迈的营收复合增速更高（7.8% vs 6.4%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
IDXX vs RMD — 直观对比
营收规模更大
RMD
是对方的1.3倍
$1.1B
营收增速更快
IDXX
高出3.3%
11.0%
净利率更高
RMD
高出4.8%
22.8%
两年增速更快
RMD
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $248.2M | $392.6M |
| 毛利率 | 60.3% | 61.8% |
| 营业利润率 | 28.9% | 34.6% |
| 净利率 | 22.8% | 27.6% |
| 营收同比 | 14.3% | 11.0% |
| 净利润同比 | 14.8% | 13.9% |
| 每股收益（稀释后） | $3.09 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $998.4M | $1.3B | ||
| Q4 24 | $954.3M | $1.3B | ||
| Q3 24 | $975.5M | $1.2B |
净利润IDXXRMD
| Q2 26 | — | $392.6M | ||
| Q1 26 | — | $398.7M | ||
| Q4 25 | $248.2M | $392.6M | ||
| Q3 25 | $274.6M | $348.5M | ||
| Q2 25 | $294.0M | $379.7M | ||
| Q1 25 | $242.7M | $365.0M | ||
| Q4 24 | $216.1M | $344.6M | ||
| Q3 24 | $232.8M | $311.4M |
毛利率IDXXRMD
| Q2 26 | — | 61.8% | ||
| Q1 26 | — | 62.2% | ||
| Q4 25 | 60.3% | 61.8% | ||
| Q3 25 | 61.8% | 61.5% | ||
| Q2 25 | 62.6% | 60.8% | ||
| Q1 25 | 62.4% | 59.3% | ||
| Q4 24 | 59.8% | 58.6% | ||
| Q3 24 | 61.1% | 58.6% |
营业利润率IDXXRMD
| Q2 26 | — | 34.6% | ||
| Q1 26 | — | 34.9% | ||
| Q4 25 | 28.9% | 34.6% | ||
| Q3 25 | 32.1% | 33.4% | ||
| Q2 25 | 33.6% | 33.7% | ||
| Q1 25 | 31.7% | 33.0% | ||
| Q4 24 | 27.4% | 32.5% | ||
| Q3 24 | 31.2% | 31.6% |
净利率IDXXRMD
| Q2 26 | — | 27.6% | ||
| Q1 26 | — | 27.9% | ||
| Q4 25 | 22.8% | 27.6% | ||
| Q3 25 | 24.8% | 26.1% | ||
| Q2 25 | 26.5% | 28.2% | ||
| Q1 25 | 24.3% | 28.3% | ||
| Q4 24 | 22.7% | 26.9% | ||
| Q3 24 | 23.9% | 25.4% |
每股收益（稀释后）IDXXRMD
| Q2 26 | — | $2.68 | ||
| Q1 26 | — | $2.74 | ||
| Q4 25 | $3.09 | $2.68 | ||
| Q3 25 | $3.40 | $2.37 | ||
| Q2 25 | $3.63 | $2.58 | ||
| Q1 25 | $2.96 | $2.48 | ||
| Q4 24 | $2.62 | $2.34 | ||
| Q3 24 | $2.80 | $2.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $1.4B |
| 总债务越低越好 | $450.0M | $663.8M |
| 股东权益账面价值 | $1.6B | $6.3B |
| 总资产 | $3.4B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资IDXXRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.7B | ||
| Q4 25 | $180.1M | $1.4B | ||
| Q3 25 | $208.2M | $1.4B | ||
| Q2 25 | $164.6M | $1.2B | ||
| Q1 25 | $164.0M | $932.7M | ||
| Q4 24 | $288.3M | $521.9M | ||
| Q3 24 | $308.6M | $426.4M |
总债务IDXXRMD
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | $664.1M | ||
| Q4 25 | $450.0M | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | $617.8M | $662.9M | ||
| Q3 24 | — | $667.6M |
股东权益IDXXRMD
| Q2 26 | — | $6.3B | ||
| Q1 26 | — | $6.5B | ||
| Q4 25 | $1.6B | $6.3B | ||
| Q3 25 | $1.6B | $6.1B | ||
| Q2 25 | $1.5B | $6.0B | ||
| Q1 25 | $1.4B | $5.5B | ||
| Q4 24 | $1.6B | $5.3B | ||
| Q3 24 | $1.6B | $5.2B |
总资产IDXXRMD
| Q2 26 | — | $8.5B | ||
| Q1 26 | — | $8.8B | ||
| Q4 25 | $3.4B | $8.5B | ||
| Q3 25 | $3.4B | $8.3B | ||
| Q2 25 | $3.3B | $8.2B | ||
| Q1 25 | $3.2B | $7.6B | ||
| Q4 24 | $3.3B | $7.1B | ||
| Q3 24 | $3.4B | $7.2B |
负债/权益比IDXXRMD
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | 0.10× | ||
| Q4 25 | 0.28× | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | 0.39× | 0.13× | ||
| Q3 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | — |
| 自由现金流经营现金流 - 资本支出 | $326.3M | — |
| 自由现金流率自由现金流/营收 | 29.9% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | — |
8季度趋势，按日历期对齐
经营现金流IDXXRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $339.7M | ||
| Q3 25 | $402.3M | $457.3M | ||
| Q2 25 | $185.7M | $538.8M | ||
| Q1 25 | $238.0M | $578.7M | ||
| Q4 24 | $262.0M | $308.6M | ||
| Q3 24 | $220.1M | $325.5M |
自由现金流IDXXRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $326.3M | $311.2M | ||
| Q3 25 | $371.2M | $414.4M | ||
| Q2 25 | $151.6M | $508.2M | ||
| Q1 25 | $207.9M | $557.9M | ||
| Q4 24 | $232.8M | $288.0M | ||
| Q3 24 | $192.0M | $307.7M |
自由现金流率IDXXRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 29.9% | 21.9% | ||
| Q3 25 | 33.6% | 31.0% | ||
| Q2 25 | 13.7% | 37.7% | ||
| Q1 25 | 20.8% | 43.2% | ||
| Q4 24 | 24.4% | 22.5% | ||
| Q3 24 | 19.7% | 25.1% |
资本支出强度IDXXRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 2.0% | ||
| Q3 25 | 2.8% | 3.2% | ||
| Q2 25 | 3.1% | 2.3% | ||
| Q1 25 | 3.0% | 1.6% | ||
| Q4 24 | 3.1% | 1.6% | ||
| Q3 24 | 2.9% | 1.5% |
现金转化率IDXXRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.87× | ||
| Q3 25 | 1.47× | 1.31× | ||
| Q2 25 | 0.63× | 1.42× | ||
| Q1 25 | 0.98× | 1.59× | ||
| Q4 24 | 1.21× | 0.90× | ||
| Q3 24 | 0.95× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RMD
暂无分部数据
